Genentech Xolair May Get FDA Advisory Committee Review In April
Executive Summary
Genentech is planning to submit additional platelet monitoring data from trials of its asthma agent Xolair in time for a potential FDA advisory committee review in late April. FDA has tentatively scheduled a meeting of its Pulmonary-Allergy Drugs Advisory Committee for April 26-27.